Avenue Therapeutics, Inc. (ATXI) Stock Price & Analysis
Avenue Therapeutics, Inc. (ATXI) rose 16.13% to USD 0.36 as of June 10, 2026 at 03:11 UTC, according to Nexqual real-time market data.
ATXI last closed at USD 0.31; the session ranged USD 0.31–0.36 on volume of 350 shares. Market capitalization is $1.19M, with a 52-week range of USD 0.15–0.97 (PNK). Source: Nexqual, June 10, 2026 at 03:11 UTC.
Key Statistics (as of June 10, 2026 at 03:11 UTC)
| Price | USD 0.36 |
|---|---|
| Change | ▲ 16.13% (up) |
| Previous Close | USD 0.31 |
| Open | USD 0.31 |
| Day Range | USD 0.31 – 0.36 |
| 52-Week Range | USD 0.15 – 0.97 |
| Volume | 350 shares |
| Market Cap | $1.19M |
| Exchange | PNK |
Technical Analysis (ATXI)
Nexqual's technical model rates ATXI "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 03:11 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.13 (neutral) |
| vs SMA50 | Below (USD 0.42) |
| MACD | -0.03 (negative) |
Analyst Ratings (ATXI)
Wall Street analysts rate ATXI "None", per Nexqual as of June 10, 2026 at 03:11 UTC.
| Consensus Rating | None |
|---|
Earnings (ATXI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -1.92 vs est -0.94 ▼ miss |
| 2024-06-30 | USD -2.41 vs est -1.05 ▼ miss |
| 2024-03-31 | USD -15.4 vs est -9 ▼ miss |
| 2023-12-31 | USD 42 vs est -7.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Financials & Fundamentals (ATXI)
| Total Revenue | $1.40M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -149.22% |
| Profit Margin | -124.79% |
| ROE | -101.08% |
| Current Ratio | 1.94 |
| Total Cash | $2.42M |
| Total Debt | $0 |
| Free Cash Flow | $-719,375 |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Financial Health Score (ATXI)
Nexqual rates Avenue Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $2M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M |
| Efficiency | Critical — ROE -101%, ROA -43.2% |
Ownership (ATXI)
| Insider Ownership | +13.51% |
|---|---|
| Institutional Ownership | +7.02% |
| Shares Outstanding | 3.29M |
| Float | 2.85M |
| Short % of Float | +2.83% |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
Leadership (ATXI)
Avenue Therapeutics, Inc. is led by Alexandra MacLean (age 57), CEO & Director, per Nexqual as of June 10, 2026 at 03:11 UTC.
| CEO & Director | Alexandra MacLean (age 57) |
|---|---|
| Interim CFO, COO & Corporate Secretary | David Jin (age 34) |
| Executive Director | Lindsay Allan Rosenwald (age 70) |
Major Backers & Investors (ATXI)
Notable institutional backers of Avenue Therapeutics, Inc. include Ikarian Capital, LLC, Boothbay Fund Management, LLC, according to Nexqual as of June 10, 2026 at 03:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 4.4% |
| Boothbay Fund Management, LLC | 1.29% |
Source: Nexqual, June 10, 2026 at 03:11 UTC.
From Avenue Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
- The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.59 | ▲ 3.6% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:11 UTC. This page is informational and not investment advice.